Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome
Autore:
Kingshott, RN; Vennelle, M; Coleman, EL; Engleman, HM; MacKay, TW; Douglas, NJ;
Indirizzi:
Univ Edinburgh, Resp Med Unit, Sleep Ctr, Edinburgh, Midlothian, Scotland Univ Edinburgh Edinburgh Midlothian Scotland burgh, Midlothian, Scotland
Titolo Testata:
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
fascicolo: 4, volume: 163, anno: 2001,
pagine: 918 - 923
SICI:
1073-449X(200103)163:4<918:RDPCTO>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITIVE AIRWAY PRESSURE; APNEA HYPOPNEA SYNDROME; LATENCY TEST; NARCOLEPSY; PERFORMANCE; DISORDERS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Kingshott, RN Univ Otago, Dept Med, Resp Res Unit, POB Box 913, Dunedin, New Zealand Univ Otago POB Box 913 Dunedin New Zealand in, New Zealand
Citazione:
R.N. Kingshott et al., "Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome", AM J R CRIT, 163(4), 2001, pp. 918-923

Abstract

Some patients with the sleep apnea/hypopnea syndrome (SAHS) remain subjectively and objectively sleepy despite using effective continuous positive airway pressure (CPAP) therapy. The aim of this single center study was to determine the efficacy and safety of the novel wake-promoting medication modafinil in the treatment of CPAP-resistant daytime sleepiness. Thirty sleep apneics receiving effective CPAP therapy (objective use, 6.5 +/- 1.1 h/night) received daily single doses of 400 mg modafinil or placebo for 2 wk in a double-blind randomized crossover design. Outcome measures were assessed atbaseline and at the end of both 2-wk treatment periods. Treatment periods were separated by a l-wk washout. Modafinil had no effect on sleepiness as measured by the Epworth Sleepiness Scale or the Multiple Sleep Latency Test(p > 0.1); however, significant improvements in alertness were found with the Maintenance of Wakefulness Test (modafinil 18.3 +/- 3.9 min; placebo, 16.6 +/- 5.0 min; p < 0.02). No significant treatment-related improvements in cognitive performance or quality of life were found with modafinil (all p> 0.05). There was a significant reduction in CPAP use on modafinil compared to placebo (6.3 +/- 1 h/night; 6.5 +/- 1, p = 0.03). This study suggeststhat modafinil may improve some aspects of alertness in patients with SAHSwho remain sleepy during CPAP therapy, but further studies are required toassess the significance of the reduction in CPAP use.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 22:13:23